Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
BRAF V600E KRAS G12D
|
colorectal cancer
|
sensitive |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
|
27312529
|
BRAF V600E
|
colorectal cancer
|
sensitive |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
|
27312529
|
BRAF V600E KRAS G13D
|
colorectal cancer
|
resistant |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
|
27312529
|
BRAF V600E MAP2K1 V211D
|
colorectal cancer
|
resistant |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
|
27312529
|
BRAF V600E MAP2K1 L115P
|
colorectal cancer
|
sensitive |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
|
27312529
|
BRAF V600E KRAS A146T
|
colorectal cancer
|
sensitive |
Cetuximab + Dabrafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).
|
27312529
|